Thromb Haemost 1997; 78(01): 684-688
DOI: 10.1055/s-0038-1657612
Prevention and treatment of deep vein thrombosis
Schattauer GmbH Stuttgart

New Approaches to Prevention of Deep Vein Thrombosis

Bergqvist David
University Hospital, Department of Surgery, Uppsala, Sweden
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

 
  • References

  • 1 Bergqvist D, Jendteg S, Johansen L, Persson K, Ӧdegaard K. The cost of long-term complications of deep venous thrombosis of the lower extremity – An analysis of a defined patient population from Sweden. Ann Intern Med. In press
  • 2 Scurr JH, Coleridge S, otj PD, Hasty JH. Deep venous thrombosis: a continuing problem BMJ. 1988; 297-228
  • 3 Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 patients. Br J Surg 1985; 72: 108-108
  • 4 Huber O, Bounemaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg 1992; 127: 310-313
  • 5 Bergqvist D, Benoni G, Bjӧrgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700
  • 6 Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228
  • 7 Dahl OE, Andreassen G, Müller C. et al The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thromb Haemost 1995; 73: 1104
  • 8 Lassen MR, Borris LC. on behalf of the Danish Prolonged Prohylaxis Study Group. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arhtroplasty a placebo-controlled trial. Drugs 1996; 52 (Suppl. 07) 47-54
  • 9 Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively Arch Intern Med. 1995; 155: 366-372
  • 10 Baglin TP. Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis. Haemostasis 1996; 26 (Suppl. 02) 10-15
  • 11 Geerts WH, Jay RM, Code RI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A compariosn of low-dose heparin with low-molecuar-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-707
  • 12 Murray DW, Britton AR, Bulstrode CJ. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg 1996; 78-B: 863-870
  • 13 Nurmohammed MT, van Riel AM, Henkens CMA, Koopman MMW, Que GTH, D’Azemar P, Büller H, ten Cate JW, Hoek JA, van der MeerJ, van der HeulC, Turpie AGG, Haley S, Sicurella J, Gent M. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75: 233-238
  • 14 Kakkar V, Cohen A, Edmondson J. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265
  • 15 Warkentin T, Levine M, Hirsh J, Horsewood P, Roberts RS, Gent M. Heparin induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335
  • 16 Jørgensen LN, Wille-Jørgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heprins. Br J Surg 1993; 80: 689-704
  • 17 Bergqvist D. Review of clinical trials of low molecular weight heparins. Eur J Surg 1992; 158: 67-78
  • 18 Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F. Orgaran (Org (10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. Thromb Haemost 1993; 70: 562-567
  • 19 Hoeck JA, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipsheer HC, ten Cate H, Büller HR, Magnani HN, ten cate JW. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992; 67: 28-32
  • 20 Turpie AGG, Gent M, Côte R, Levine MN, Ginsberg JS, Powers PJ, Leclerc J, Geerts W, Jay R, Neemeh J, Klimek M, Hirsh J. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann Intern Med 1992; 117: 353-357
  • 21 Bergqvist D, Kettunen K, Fredin H, Faunø P, Suomalainen O, Soimakallio S, Karjalainen P, Cederholm C, Jensen LJ, Justesen T, Stiekema J. Thromboprophylaxis in hip fracture patients -a prospective randomized comparative study between Org 10172 and dextran 70. Surgery 1991; 109: 617-622
  • 22 Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture in the hip. J Bone Joint Surg 1991; 73-A: 494-502
  • 23 Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-561
  • 24 Prandoni P, Meduri F, Cuppini S, Toniato A, Zangrandi F, Polistena P, Gianese F, Maffei Faccioli A. Dermatan sulphate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-509
  • 25 Agnelli G, Cosmi B, Di Filippo P, Rannucci V, Veschi F, Longetti M, Denga C, Barzi F, Gianese F, Lupatelli L, Rinonapoli E, Nenci G. A randomized, double-bliind, placebo-controlled trial of dermatan sulphate for prevetion of deep-vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-208
  • 26 Cohen AT, Phillips MJ, Edmondson RA, Skinner JA, Das SK, Cooper DJ, Thomas EM, Melissari E, Kakkar VV. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Thromb Haemost 1994; 72: 793-798
  • 27 Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P. Direct thrombin inhibition with Rec-Hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-231
  • 28 Eriksson B, Ekman S, Lindbratt S, Baur M, Bach D, Tӧrholm C, Kälebo P, Close P. Prevention of thromboembolism after total hip replacement with recombinant hirudin. Results of a double-blind multicenter trial comparing the efficacy of 15 mg desirudin (™Revasc) with unfractionated heparin. J Bone Joint Surg. 1996. In press
  • 29 Eriksson BI, Wille Jørgensen, Kälebo P, Mouret P, Rosencher N, Bӧsch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P. Recombinant hirudin, desirudin, is more effective than a low-molecular-weight heparin, enoxaparin, as prophylaxis of major thromboembolic complications after primary total hip replacement. Manuscript.
  • 30 Ginsberg JS, Nurmohammed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG, Wietz J, Buller HR, ten Cate JW, Neemeh J, Adelman B, Fox I, Maraganore J, Hirsh J. Use of hirulog in the prevention of venous thrombosis after major hip knee surgery. Circulation 1994; 90: 2385-2389
  • 31 Kakkar VV. Randomized controlled double-blind trial of LMWH (ROII) and standard heparin in prevention of venous thromboembolism after total hip replacement. Haemostasis 1996; 26 (Suppl. 03) 623 (Abstrakt)
  • 32 Antiplatelet Trialists’ Collaboration: collaborative overview of randomized trials of antiplatelet therapy III. Reduction of venous thrombosis and pulmonary embolism by antiplatel prophylaxis among surgical and medical patients. Br Med J. 1994 4 308. 235-246
  • 33 Stranks GJ, MacKenzie NA, Grover ML, Fail T. The A-V impulse system reduces deep-vein thrombosis and swelling after hemiarthroplasty for hip fracture. J Bone Joint Surg 1992; 74-B: 775-778
  • 34 Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein thrombosis in total hip replacement. J Bone Joint Surg 1994; 76-B: 579-583
  • 35 Fordyce MJF, Ling RSM. A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg 1992; 74-B: 45-49
  • 36 Wilson NV, Das SK, Kakkar VV, Maurice HD, Smiberg JG, Thomas EM, Nixon JE. Thrombo-embolic prophylaxis in total knee replacement. J Bone Joint Surg 1992; 74-B: 50-52
  • 37 Bradley JG, Krugener GH, Jager HJ. The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty. J Arthroplasty 1993; 08: 57-61
  • 38 Bergqvist D, Fredin H. Pulmonary embolism and mortality in patients with fractured hips – a prospective consecutive series. Eur J Surg 1991; 157: 571-574
  • 39 Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br 1995; 77: 06-10
  • 40 Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. Br J Surg 1996; 83: 1394-1395
  • 41 Svensson P, Benoni G, Fredin H, Bjӧrgell O, Nilsson P, Hedlundh U, Nylander G, Bergqvist D, Dahlbäck B. Female gender and resistance to activated protein C (FV R 506Q) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost. Submitted